ArticlePloS one2013
ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 60 citations in OpenAlex.
- Molecular biomarkers of progression in non-muscle-invasive bladder cancer - beyond conventional risk stratification.Nature reviews. Urology · 2025Review
- The Role of SWI/SNF Complex in Bladder Cancer.Journal of cellular and molecular medicine · 2025Review
- SWI/SNF complex alterations predict immunotherapy response in bladder cancer.Frontiers in immunology · 2025Article
- De novo variation in ARID1B gene causes Coffin-Siris syndrome 1 in a Chinese family with excessive early-onset high myopia.BMC medical genomics · 2024Article
- Review
- The somatic mutational landscape and role of the ARID1A gene in hepatocellular carcinoma.Heliyon · 2023Article
- Urothelial Carcinoma: Divergent Differentiation and Morphologic Subtypes.Surgical pathology clinics · 2022Review
- Article
- Role of ARID1A in the Regulation of Human Trophoblast Migration and Invasion.Reproductive sciences (Thousand Oaks, Calif.) · 2022Article
- Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study.European urology open science · 2022Article
- SWI/SNF chromatin remodeling complex alterations in meningioma.Journal of cancer research and clinical oncology · 2021Article
- Targeted Deep Sequencing of Bladder Tumors Reveals Novel Associations between Cancer Gene Mutations and Mutational Signatures with Major Risk Factors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- ARID1A upregulation predicts better survival in patients with urothelial bladder carcinoma.The Journal of international medical research · 2020Article
- Diesel exhaust and bladder cancer risk by pathologic stage and grade subtypes.Environment international · 2020Article
- Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status.Scientific reports · 2019Article
- Histone Deacetylase Inhibition Has Targeted Clinical Benefit inMolecular cancer therapeutics · 2019Article
- Epigenetic Alterations in Bladder Cancer.Current urology reports · 2018Review
- New therapeutic options opened by the molecular classification of gastric cancer.World journal of gastroenterology · 2018Review
- Unmasking molecular profiles of bladder cancer.Investigative and clinical urology · 2018Review
- The diagnostic role of PTEN and ARID1A in serous effusions.Virchows Archiv : an international journal of pathology · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urothelial bladder cancer (UBC) is heterogeneous at the clinical, pathological, genetic, and epigenetic levels. Exome sequencing has identified ARID1A as a novel tumor suppressor gene coding for a chromatin remodeling protein that is mutated in UBC. Here, we assess ARID1A alterations in two series of patients with UBC. In the first tumor series, we analyze exons 2-20 in 52 primary UBC and find that all mutant tumors belong to the aggressive UBC phenotype (high grade non-muscle invasive and muscle invasive tumors) (P = 0.05). In a second series (n = 84), we assess ARID1A expression using immunohistochemistry, a surrogate for mutation analysis, and find that loss of expression increases with higher stage/grade, it is inversely associated with FGFR3 overexpression (P = 0.03) but it is not correlated with p53 overexpression (P = 0.30). We also analyzed the expression of cytokeratins in the same set of tumor and find, using unsupervised clustering, that tumors with ARID1A loss of expression are generally KRT5/6-low. In this patient series, loss of ARID1A expression is also associated with worse prognosis, likely reflecting the higher prevalence of losses found in tumors of higher stage and grade. The independent findings in these two sets of patients strongly support the notion that ARID1A inactivation is a key player in bladder carcinogenesis occurring predominantly in FGFR3 wild type tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.